阿司匹林对胃癌化学预防效应的累积剂量阈值
该研究基于韩国国民健康保险服务(NHIS)人群纵向队列,纳入461,489人,观察2007至2012年胃癌新发病例,并回顾2002至2006年药房索赔数据以限定日剂量(DDD)系统评估累积用药暴露。结果显示,与未使用者相比,阿司匹林累积使用≥3 DDD-年者胃癌风险降低,3-4 DDD-年者调整HR为0.79(95%CI 0.63-0.98),4-5 DDD-年者为0.63(95%CI 0.48-0.83),趋势P<0.001。结论认为在韩国一般人群中,累积剂量>3 DDD-年的长期阿司匹林使用与胃癌发病率降低相关。
要点
- 阿司匹林累积使用≥3 DDD-年与胃癌风险降低相关。
- 3-4 DDD-年者调整HR为0.79(95%CI 0.63-0.98)。
- 4-5 DDD-年者调整HR为0.63(95%CI 0.48-0.83),趋势P<0.001。
核心结论
- 在韩国一般人群中,累积剂量>3 DDD-年的长期阿司匹林使用与胃癌发病率降低相关。
研究设计与样本
- 基于韩国国民健康保险服务(NHIS)人群纵向队列,纳入461,489人,观察2007至2012年以识别胃癌新发病例,并回顾2002至2006年药房索赔数据以限定日剂量(DDD)系统评估累积用药暴露。
主要发现
- 随访2,965,500人-年共识别5,674例胃癌新发病例,总发病率为191.00例/10万人-年。
- 与未使用者相比,阿司匹林累积使用3-4 DDD-年者胃癌调整HR为0.79(95%CI 0.63-0.98),4-5 DDD-年者为0.63(95%CI 0.48-0.83),趋势P<0.001。
- 倾向评分匹配和巢式病例对照设计的敏感性分析一致显示阿司匹林的化学预防效应。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Many studies have found evidence that aspirin has protective effects against certain cancers, but quantitative dose-response data have been available only on a limited basis. This study aimed to confirm the dose-response relationship of aspirin usage and gastric cancer and to estimate the cumulative dose threshold of aspirin to achieve protective effects against gastric cancer in the general population. METHODS: A total of 461,489 individuals in a population-based longitudinal cohort provided by the National Health Insurance Services (NHIS) in the Republic of Korea were observed from 2007 to 2012 to identify gastric cancer incident cases. The pharmacy claims data of these individuals from 2002 to 2006 were reviewed to assess cumulative medication exposure using the defined daily dose (DDD) system. Hazard ratios (HRs) of aspirin use for gastric cancer were estimated using multivariate Cox Proportional Hazard regression. Sensitivity analyses, including propensity-score matching and a nested case-control design, were performed to evaluate the variability caused by study design. RESULTS: A total of 5674 incident gastric cancers were identified from 2,965,500 person-years of follow-up observation, giving an overall incidence rate of 191.00 gastric cancers per 100,000 person-years. Compared to non-users, those with aspirin use of ≥3 DDD-years showed a statistically significant protective effect of aspirin use against gastric cancer; the adjusted HR (95% confidence intervals) were 0.79 (0.63-0.98) and 0.63 (0.48-0.83) for those with aspirin use of 3-4 DDD-years and 4-5 DDD-years, respectively (P for trend < 0.001). Sensitivity analyses using propensity-score matching and a nested case-control design consistently showed a chemopreventive effect of aspirin. CONCLUSION: Long-term aspirin use was associated with reduced gastric cancer incidence in the general population of South Korea when the cumulative dose was >3 DDD-years.
引用
- Kim MH, Chang J, Kim WJ, et al. Cumulative Dose Threshold for the Chemopreventive Effect of Aspirin Against Gastric Cancer. Am J Gastroenterol. 2018. PMID: 29855546. doi:10.1038/s41395-018-0097-5
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。